Isatuximab

Monoclonal antibody

Also known as SAR650984

Approvedregulatory verdict

Evidence outlook

Approved: Multiple Myeloma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (4)
EU
  • Sarclisa with bortezomib, lenalidomide and dexamethasone (VRd) for newly diagnosed multiple myeloma not eligible for transplantsanofi.com
  • Sarclisa: relapsed and refractory multiple myeloma (combination regimens)EMA
Product first approved 2020
JP
  • Sarclisa (Sanofi K.K.): relapsed or refractory multiple myeloma with pomalidomide and dexamethasone
sanofi.com
CN
  • Sarclisa in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
sanofi.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (15)
Multiple Myeloma
NCT07903506 · Kite, A Gilead Company
2027-02 – 2042-03 · Newly Diagnosed Multiple Myeloma
What this study did
NCT07624513 · Dana-Farber Cancer Institute
2026-08-31 – 2038-03-01 · Multiple Myeloma
What this study did
NCT07764978 · AstraZeneca
2026-06-26 – 2034-05-12 · Newly Diagnosed Multiple Myeloma
What this study did
NCT04270409 · Sanofi
2020-06-16 – 2033-10-21 · Plasma Cell Myeloma
What this study did
NCT04483739 · European Myeloma Network B.V.
2020-09-25 – 2032-12-31 · Multiple Myeloma
What this study did
NCT06216158 · University of Heidelberg Medical Center
2024-04-05 – 2029-06 · Multiple Myeloma
What this study did
NCT05558319 · PETHEMA Foundation
2022-11-10 – 2029-04 · Newly Diagnosed Multiple Myeloma
What this study did
NCT04934475 · Intergroupe Francophone du Myelome
2021-12-08 – 2028-09-30 · Multiple Myeloma
What this study did
NCT03617731 · University of Heidelberg Medical Center
2018-10-18 – 2028-06 · Multiple Myeloma
What this study did
NCT05405166 · Sanofi
2022-06-23 – 2027-10-22 · Plasma Cell Myeloma Recurrent
What this study did
NCT05804032 · University of Heidelberg Medical Center
2023-04-14 – 2026-01-30 · Multiple Myeloma
What this study did
Phase 2/3 (3)
Multiple Myeloma
NCT07732712 · The Affiliated People's Hospital of Ningbo University
2027-01-01 – 2030-12-31 · Multiple Myeloma
What this study did
NCT05665140 · University Hopsital Schleswig Holstein Campus Lübeck
2023-02-03 – 2028-10 · Newly Diagnosed Multiple Myeloma
What this study did
Other / comorbidity
NCT06860269 · Assistance Publique - Hôpitaux de Paris
2025-05-06 – 2035-03-15 · Acute Lymphoblastic Leukemia
What this study did
Phase 2 (50)
Multiple Myeloma
NCT05145400 · UNC Lineberger Comprehensive Cancer Center
2022-02-18 – 2033-05-28 · Multiple Myeloma, Cancer
What this study did
NCT04558931 · Karolinska Institutet
2021-06-02 – 2032-12-31 · Multiple Myeloma
What this study did
NCT04883242 · University of Washington
2021-07-29 – 2031-12-31 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT05272826 · Canadian Myeloma Research Group
2024-12-12 – 2031-03 · Multiple Myeloma
What this study did
NCT05922501 · Massachusetts General Hospital
2024-05-31 – 2030-12-31 · Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma
What this study did
NCT04240054 · Medical College of Wisconsin
2021-11-02 – 2030-12-01 · Multiple Myeloma
What this study did
NCT05344833 · University of Illinois at Chicago
2023-01-05 – 2030-12 · Multiple Myeloma
What this study did
NCT02960555 · M.D. Anderson Cancer Center
2017-02-08 – 2030-04-30 · Smoldering Plasma Cell Myeloma
What this study did
NCT07045909 · PETHEMA Foundation
2025-06-30 – 2030-03-31 · De Novo Multiple Myeloma, Anitocabtagene Autoleucel
What this study did
NCT04850599 · OHSU Knight Cancer Institute
2022-06-14 – 2029-02-21 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT04653246 · Jacob Laubach, MD
2021-07-13 – 2029-01-13 · Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant
What this study did
NCT07585760 · Institute of Hematology & Blood Diseases Hospital, China
2026-09-10 – 2028-12-30 · Multiple Myeloma (MM), Multiple Myeloma Light Chain Induced Renal Insufficiency
What this study did
NCT07828522 · Institute of Hematology & Blood Diseases Hospital, China
2026-10-01 – 2028-12-30 · Multiple Myeloma (MM), Transplant-eligible Patients
What this study did
NCT06832865 · Massachusetts General Hospital
2025-08-14 – 2028-12-01 · Relapsed Refractory Multiple Myeloma (RRMM), Relapsed Refractory Multiple Myeloma
What this study did
NCT04891809 · Arbeitsgemeinschaft medikamentoese Tumortherapie
2021-10-20 – 2028-12 · Newly Diagnosed Multiple Myeloma
What this study did
NCT04786028 · Canadian Myeloma Research Group
2021-12-08 – 2028-12 · Multiple Myeloma
What this study did
NCT05669989 · Sanofi
2023-04-05 – 2028-11-30 · Plasma Cell Myeloma
What this study did
NCT07789522 · Institute of Hematology & Blood Diseases Hospital, China
2026-10-01 – 2028-10-30 · Multiple Myeloma (MM)
What this study did
NCT05704049 · Sanofi
2023-04-05 – 2028-05-12 · Relapsed/Refractory Multiple Myeloma
What this study did
NCT05911321 · UNC Lineberger Comprehensive Cancer Center
2023-12-05 – 2028-03-26 · Multiple Myeloma, Relapse, Refractory, Aging, Co-morbidity
What this study did
NCT05776979 · M.D. Anderson Cancer Center
2023-08-17 – 2027-12-31 · Multiple Myeloma
What this study did
NCT05123131 · Cancer Trials Ireland
2022-04-01 – 2027-12-15 · Multiple Myeloma
What this study did
NCT06517017 · University of Utah
2025-10-09 – 2027-11 · Multiple Myeloma, Plasma Cell Leukemia
What this study did
NCT05690984 · Medical College of Wisconsin
2023-06-26 – 2027-08 · Multiple Myeloma
What this study did
NCT06356571 · Sanofi
2025-03-17 – 2027-07-15 · Plasma Cell Myeloma Refractory
What this study did
NCT05346809 · Divaya Bhutani
2023-03-31 – 2027-07 · Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult
What this study did
NCT04835129 · Medical College of Wisconsin
2022-01-10 – 2027-06-01 · Multiple Myeloma
What this study did
NCT04965155 · EMN Trial Office S.r.l. Impresa Sociale
2021-03-21 – 2027-03-31 · Relapsed Multiple Myeloma
What this study did
KRDI in Transplant-Eligible MMactive not recruiting
NCT04430894 · Massachusetts General Hospital
2020-07-10 – 2026-12-30 · Multiple Myeloma
What this study did
NCT03104842 · Universitätsklinikum Hamburg-Eppendorf
2017-08-15 – 2026-09 · Multiple Myeloma
What this study did
NCT04287855 · Poitiers University Hospital
2020-08-28 – 2026-04-15 · Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
What this study did
NCT05298683 · Hellenic Society of Hematology
2022-05 – 2026-01 · Multiple Myeloma, Renal Impairment, Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases
What this study did
NCT05147493 · Hellenic Society of Hematology
2022-04 – 2025-02 · Multiple Myeloma, Renal Impairment, Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases
What this study did
NCT04939844 · Oslo University Hospital
2021-06-29 – 2024-08-31 · Multiple Myeloma
What this study did
NCT05114109 · Assistance Publique - Hôpitaux de Paris
2021-11-01 – 2023-12-31 · Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Cryoglobulinemic Vasculitis
What this study did
NCT04802031 · Thomas Martin, MD
2021-05-28 – 2022-12-31 · Relapsed Multiple Myeloma, Refractory Multiple Myeloma
What this study did
Other / comorbidity
NCT06762769 · University College, London
2025-06-02 – 2032-11-01 · Smouldering Myeloma
What this study did
NCT07652905 · Institute of Hematology & Blood Diseases Hospital, China
2026-09-15 – 2031-12-30 · Plasma Cell Leukemia (PCL)
What this study did
NCT07903623 · Institute of Hematology & Blood Diseases Hospital, China
2026-10-25 – 2031-12-30 · Primary Plasma Cell Leukemia
What this study did
NCT06648889 · Goethe University
2024-10-22 – 2030-06 · T-ALL
What this study did
NCT05873205 · Memorial Sloan Kettering Cancer Center
2023-07-21 – 2027-06-29 · Blood Cancer, Refractory Immune Cytopenias
What this study did
NCT05559827 · Assistance Publique - Hôpitaux de Paris
2022-09 – 2026-10 · Immunological Pure Red Cell Aplasia
What this study did
NCT04763616 · Won Seog Kim
2021-06-25 – 2026-04-01 · Natural Killer/T-cell Lymphoma, Relapsed Natural Killer/T-cell Lymphoma, Refractory Natural Killer/T-cell Lymphoma
What this study did
NCT05066607 · Intergroupe Francophone du Myelome
2022-02-11 – 2026-03 · AL Amyloidosis
What this study did
NCT04943302 · Tufts Medical Center
2022-09-01 – 2026-01 · Amyloidosis, Light Chain (AL) Amyloidosis
What this study did
NCT04614558 · Columbia University
2021-06-08 – 2025-11-09 · Monoclonal Gammopathy
What this study did
NCT03499808 · SWOG Cancer Research Network
2018-06-06 – 2023-09-19 · Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea, Early Satiety, Gastrointestinal Hemorrhage, Hepatomegaly, Lymphadenopathy, Macroglossia, Nausea, Primary Systemic Amyloidosis, Purpura, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis
What this study did
NCT04661033 · Sanofi
2021-09-09 – 2023-06-26 · Warm Autoimmune Hemolytic Anemia (wAIHA)
What this study did
NCT03860844 · Sanofi
2019-08-06 – 2023-05-26 · Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
What this study did
NCT02999633 · Sanofi
2017-03-08 – 2017-11-14 · T-cell Type Acute Leukemia-Precursor, T-lymphoblastic Lymphoma/Leukaemia
What this study did
Phase 1/2 (17)
Multiple Myeloma
NCT07600151 · Universitätsklinikum Hamburg-Eppendorf
2026-12-01 – 2036-12-31 · Myeloma Multiple, Myeloma
What this study did
NCT07601100 · Dana-Farber Cancer Institute
2026-09-03 – 2034-07-01 · Newly Diagnosed Multiple Myeloma
What this study did
NCT06119685 · Indapta Therapeutics, INC.
2023-10-25 – 2029-12-31 · NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
What this study did
NCT07479979 · Natalie Callander
2026-05-21 – 2029-07 · Relapse Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT04643002 · Sanofi
2021-01-25 – 2028-04-20 · Plasma Cell Myeloma Refractory
What this study did
NCT04126200 · GlaxoSmithKline
2019-10-07 – 2027-03-11 · Multiple Myeloma
What this study did
NCT07217184 · GlaxoSmithKline
2021-07-29 – 2027-03-11 · Multiple Myeloma
What this study did
NCT03194867 · Sanofi
2018-02-21 – 2023-04-05 · Plasma Cell Myeloma
What this study did
NCT02812706 · Sanofi
2016-09-05 – 2022-09-28 · Multiple Myeloma
What this study did
Other / comorbidity
NCT07714512 · Institute of Hematology & Blood Diseases Hospital, China
2026-06-30 – 2028-12-31 · Aplastic Anemia
What this study did
NCT01084252 · Sanofi
2010-05-11 – 2023-07-13 · Hematological Malignancy
What this study did
NCT03769181 · Sanofi
2018-12-11 – 2022-11-08 · Lymphoma
What this study did
NCT03555149 · Hoffmann-La Roche
2018-09-27 – 2022-09-26 · Colorectal Cancer
What this study did
NCT04294459 · Sanofi
2020-06-18 – 2022-05-02 · Immune System Disorder
What this study did
NCT03367819 · Sanofi
2018-01-04 – 2021-03-10 · Prostate Cancer, Non-small Cell Lung Cancer
What this study did
Phase 1 (15)
Multiple Myeloma
NCT06203912 · Elvira Umyarova
2024-03-05 – 2026-06-16 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT02332850 · Thomas Martin, MD
2015-01-21 – 2025-12-31 · Multiple Myeloma
What this study did
NCT04045795 · Sanofi
2019-08-06 – 2024-03-27 · Multiple Myeloma
What this study did
NCT04083898 · Washington University School of Medicine
2020-04-03 – 2024-03-07 · Multiple Myeloma
What this study did
NCT04912427 · Washington University School of Medicine
2022-04-01 – 2024-01-26 · Multiple Myeloma
What this study did
NCT01749969 · Sanofi
2013-02-06 – 2023-06-20 · Plasma Cell Myeloma
What this study did
NCT02514668 · Sanofi
2015-09-01 – 2021-12-02 · Plasma Cell Myeloma
What this study did
NCT02283775 · Sanofi
2015-05-15 – 2021-05-26 · Plasma Cell Myeloma
What this study did
Other / comorbidity
NCT04754945 · Emory University
2021-04-28 – 2028-07-24 · AL Amyloidosis
What this study did
NCT05862766 · NYU Langone Health
2024-12-01 – 2027-01-01 · Antibody-mediated Rejection, Allosensitization
What this study did
NCT05284032 · Firas El Chaer, MD
2022-11-29 – 2024-06-11 · Platelet Refractoriness, Hematologic Malignancy
What this study did
Phase 4 (1)
Multiple Myeloma
Isa-VRD in TIE HRMMnot yet recruiting
NCT07334535 · Peking Union Medical College Hospital
2026-01-30 – 2029-01 · Multiple Myeloma
What this study did
Early phase / not applicable (2)
Multiple Myeloma
NCT05889221 · Poitiers University Hospital
2023-10-23 – 2028-09-01 · Multiple Myeloma, Myeloma Multiple, Myeloma
What this study did
NCT05053607 · Pack Health
2022-06-17 – 2025-12-31 · Multiple Myeloma, Refractory Multiple Myeloma
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Multiple Myeloma
NCT06182774 · Canadian Cancer Trials Group
2024-04-10 – 2032-07-31 · Multiple Myeloma
What this study did
NCT05675319 · Universitätsklinikum Hamburg-Eppendorf
2023-03-03 – 2025-03-21 · Multiple Myeloma
What this study did

Competitive landscape

This mechanism is crowded: 13 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Multiple Myeloma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Isatuximab: this drugApprovedMonoclonal antibodyCD38Partial signal
NCT02990338: Progression Free Survival (PFS) (From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration: 76.7 weeks)): IPd (Isatuximab + Pomalidomide + Dexamethasone) 11.53 months (95% CI 8.936 to 13.897) vs Pd (Pomalidomide + Dexamethasone) 6.47 months (95% CI 4.468 to 8.279)
Belantamab MafodotinApprovedAntibody–drug conjugateBCMAPartial signal
NCT04246047: Progression-free Survival (PFS) (Up to approximately 41 months): Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) 36.6 Months vs Daratumumab + Bor + Dex 13.4 Months (95% CI 11.1 to 17.5)
NCT04162210: Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG) (Up to 27 months): Belantamab Mafodotin 11.2 Months (95% CI 6.4 to 14.5) vs Pomalidomide Plus Dexamethasone 7 Months (95% CI 4.6 to 10.6) missed
BortezomibApprovedSmall moleculeProteasomePartial signal
NCT00722566: Number of Patients With Overall Response (Complete Response + Partial Response) (Over 4 cycles (prior to the addition of dexamethasone)): VELCADE Subcutaneuous 61/145 | VELCADE Intravenous 31/73
NCT00048230: Response rate (CR+PR): 38% bortezomib vs 18% dexamethasone (P<0.001), with CR 6% vs <1%; median time to progression 6.22 vs 3.49 months (HR 0.55, P<0.001); 1-year survival 80% vs 66% (P=0.003), overall survival HR 0.57 (P=0.001).
CarfilzomibApprovedSmall moleculeProteasomePartial signal
NCT03158688: Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Kd - Carfilzomib and Dexamethasone — Participants with PFS events: 68 Participants; Participants who were censored: 86 Participants | KdD - Carfilzomib, Dexamethasone and Daratumumab — Participants with PFS events: 110 Participants; Participants who were censored: 202 Participants
NCT01568866: Progression-free Survival (From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively): Carfilzomib + DEX 18.7 months vs Bortezomib + DEX 9.4 months (95% CI 8.4 to 10.4)
Ciltacabtagene AutoleucelApprovedCell therapyBCMAPartial signal
NCT04181827: Progression-free survival: median not reached with cilta-cel vs 11.8 months with standard care (hazard ratio 0.26; 95% CI 0.18 to 0.38; P<0.001); 12-month PFS 75.9% vs 48.6% (CARTITUDE-4, N Engl J Med 2023).
DaratumumabApprovedMonoclonal antibodyCD38Partial signal
NCT03901963: Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS) (From randomization up to 12 months): Daratumumab + Lenalidomide 50.5% (95% CI 40.3 to 60.7) vs Lenalidomide 18.8% (95% CI 11.7 to 27.8)
NCT02076009: Progression-free survival at the interim analysis: hazard ratio 0.37 (95% CI 0.27 to 0.52; P<0.001); 12-month PFS 83.2% with daratumumab plus lenalidomide/dexamethasone vs 60.1% with lenalidomide/dexamethasone (POLLUX, N Engl J Med 2016).
ElotuzumabApprovedMonoclonal antibodySLAMF7 (CS1/CD319)Partial signal
NCT01335399: Progression-Free Survival (PFS) (From randomization to date of first documented tumor progression or death due to any cause (up to 8 years)): E-Ld Cohort 31.38 Months (95% CI 26.18 to 36.8) vs Ld Cohort 29.47 Months (95% CI 23.49 to 34.3) missed
NCT01239797: Median Progression Free Survival (PFS) (From randomization up to 326 events (up to approximately 38 months)): Lenalidomide + Dexamethasone + Elotuzumab 19.35 Months (95% CI 16.62 to 22.18) vs Lenalidomide + Dexamethasone 14.85 Months (95% CI 12.09 to 17.22)
ElranatamabApprovedMultispecific antibodyBCMA x CD3Weak signalFeatured results are non-efficacy only in this race
Iberdomide (Zenbexus)ApprovedSmall moleculeCereblon E3 ubiquitin-ligasenot yet gradedNo reviewed efficacy summary in this indication
Idecabtagene VicleucelApprovedCell therapyBCMAReliable signal
NCT03651128: PFS 13.3 vs 4.4 mo (HR 0.49 [95% CI 0.38-0.65], p<0.001); ORR 71% vs 42% (p<0.001)
NCT03361748: Overall Response Rate (From first dose to 24 Months): BB2121 74.5% (95% CI 67.1 to 81.8)
IxazomibApprovedSmall moleculeProteasomeReliable signal
NCT02312258: Progression Free Survival (PFS) (From randomization until PD or death (up to 52 months)): Ixazomib 17.4 months (95% CI 14.78 to 20.3) vs Placebo 9.4 months (95% CI 8.51 to 11.47)
NCT02181413: Progression Free Survival (PFS) (Randomization up to End of treatment (EOT) (24 months); thereafter followed up every 4 weeks (up to 45 months)): Ixazomib Citrate 26.5 months (95% CI 23.69 to 33.81) vs Placebo 21.3 months (95% CI 17.97 to 24.67)
LenalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligase, Thalidomide AnalogReliable signal
NCT00424047: Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (From randomization up to cut-off date of 03 August 2005; up to 24 months): Lenalidomide Plus Dexamethasone 52.1 weeks vs Placebo Plus Dexamethasone 20.1 weeks (95% CI 16.6 to 20.7)
NCT00056160: Time to Tumor Progression (TTP) (60 weeks (median Time To Progression of CC-5013/Dex treatment group)): CC-5013/Dex 60.1 Weeks (95% CI 41.1 to 80) vs Placebo/Dex 20.1 Weeks (95% CI 16.1 to 21.1)
LinvoseltamabApprovedMultispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Melphalan Hydrochloride (Evomela)ApprovedSmall moleculeDNA (guanine N7 position)Weak signal
NCT03159702: Progression-free Survival (PFS) of Participants With Hematological Malignancies Undergoing Treatment. (1 year): MEL/FLU and Total-Body Irradiation (TBI) 17/43
MotixafortideApprovedPeptideCXCR4Partial signal
NCT03246529: Proportion of patients who collected at least 6 x 10^6 CD34+ cells/kg in up to 2 aphereses (central laboratory), randomized Part 2, motixafortide + filgrastim (n=80) vs placebo + filgrastim (n=42): 67.5% vs 9.5%, adjusted difference 56.8%, p < 0.0001 (stratified Cochran-Mantel-Haenszel; APHEXDA US label, section 14). CT.gov posted results for the same randomized groups give 70.0% vs 14.3%, p < 0.0001 (Cochran-Mantel-Haenszel).
NCT02639559: Number of Donors That Mobilize ≥ 2 x 10^6 CD34+ Cells/kg of Recipients Weight After a Single Injection of BL-8040 After no More Than Two Leukapheresis Collections (Arm 1 - Donors Only) (Up to Day 2): Arm 1: Donors 22/24
PlerixaforApprovedSmall moleculeCXCR4Partial signal
NCT00103662: Collection of at least 6 x 10^6 CD34+ cells/kg in 2 or fewer aphereses: plerixafor plus G-CSF 71.6% (106/148) vs placebo plus G-CSF 34.4% (53/154), P<.001 (DiPersio et al., Blood 2009).
PomalidomideApprovedSmall moleculeCereblon (CRBN)Partial signal
NCT01324947: Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment (From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.): Pomalidomide 23%
NCT01311687: Progression-free Survival (PFS) - Primary Analysis (From randomization until the data cut-off date of 07 September 2012. Maximum duration of follow-up for PFS assessments was 57 weeks.): Pomalidomide Plus Low-Dose Dexamethasone 15.7 weeks (95% CI 13 to 20.1) vs High-Dose Dexamethasone 8 weeks (95% CI 7 to 9)
SelinexorApprovedSmall moleculeXPO1 (exportin-1)Partial signal
NCT03110562: SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC) (From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 33 months)): SVd Arm: Selinexor + Bortezomib + Dexamethasone 13.93 Months vs Vd Arm: Bortezomib + Dexamethasone 9.46 Months (95% CI 8.11 to 10.78)
TalquetamabApprovedMultispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
TeclistamabApprovedMultispecific antibodyBCMA x CD3Partial signal
NCT05083169: Primary endpoint, progression-free survival: teclistamab plus daratumumab was statistically significant and superior to DPd/DVd (J&J, 2025-10-16).
NCT04696809: Phase 2 primary endpoint ORR 76.9% (>=VGPR 76.9%, >=CR 65.4%) in 26 patients at RP2D 1.5 mg/kg; median follow-up 14.32 months
ThalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligasePartial signalFeatured results are non-efficacy only in this race
Zoledronic Acid (Zometa)ApprovedSmall moleculeFarnesyl pyrophosphate synthase (FPPS)not yet gradedNo reviewed efficacy summary in this indication
PanobinostatUS approval withdrawnSmall moleculeHDACPartial signal
NCT01023308: Progression-free survival (investigator-assessed): median 11.99 months with panobinostat + bortezomib + dexamethasone vs 8.08 months with placebo + bortezomib + dexamethasone; HR 0.63 (95% CI 0.52-0.76), p<0.0001 (Lancet Oncology 2014)
Anitocabtagene AutoleucelPhase 3Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
Arlocabtagene AutoleucelPhase 3Cell therapyGPRC5DWeak signalFeatured results are safety only in this race
AZD0120Phase 3Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
BCD-264Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
CevostamabPhase 3Multispecific antibodyFcRH5 (FcRL5) x CD3not yet gradedNo reviewed efficacy summary in this indication
CT-P44Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
Denosumab (Xgeva)Phase 3Monoclonal antibodyRANKLReliable signal
NCT01345019: Time to First On-study Skeletal Related Event (From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.): Denosumab 695 days vs Zoledronic Acid 730 days (95% CI 504 to 1014)
Equecabtagene AutoleucelPhase 3Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
EtentamigPhase 3Multispecific antibodyBCMA x CD3Partial signal
NCT06158841: Dual primary endpoints met: objective response rate and progression-free survival vs standard available therapies (PFS HR 0.40, P<0.0001) (AbbVie, 2026-09-03).
F182112Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
FelzartamabPhase 3Monoclonal antibodyCD38Partial signal
NCT03952091: Median PFS: 18·9 months felzartamab+Rd vs 10·4 months Rd (hazard ratio 0·62; p=0·0035)
Gamgertamig (CM336)Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
HLX15Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
IBI3003Phase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
InobrodibPhase 3Small moleculeCBP/p300 (bromodomain)not yet gradedNo reviewed efficacy summary in this indication
LumrotatugPhase 3Monoclonal antibodyCD38Weak signal
NCT04818372: CM313 phase 1 dose-escalation/expansion (NCT04818372, anti-CD38 mAb, R/R multiple myeloma + marginal zone lymphoma): grade>=3 TEAEs 15/34 (44.1%), no DLTs; ORR 34.5% among 29 evaluable RRMM patients; median PFS 132 days.
Mezagitamab
Phase 3(overall)
Monoclonal antibodyCD38
Weak signal(overall)
Featured results are safety only in this race
MezigdomidePhase 3Small moleculeCereblon E3 ubiquitin-ligasePartial signal
NCT05552976: Primary endpoint, progression-free survival: statistically significant and clinically meaningful improvement vs carfilzomib and dexamethasone (Bristol Myers Squibb, 2026-03-09).
PlitidepsinPhase 3Small moleculeeEF1A2 (eukaryotic translation elongation factor 1-alpha 2)Partial signal
NCT01102426: Progression Free Survival (PFS) as Per Intention-to-treat (ITT) (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years): Plitidepsin+Dexamethasone 2.6 months (95% CI 1.9 to 3) vs Dexamethasone 1.7 months (95% CI 1.1 to 2)
QL2109Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
QLS32015Phase 3Multispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
QLS4131Phase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
RamantamigPhase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
SanritatugPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
SCTC21CPhase 3Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
TorutamigPhase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
TQB2934Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Velinotamig (GR1803)Phase 3Multispecific antibodyBCMA x CD3Weak signalNo reviewed efficacy summary in this indication
VenetoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
Burixafor (TG-0054)Phase 2Small moleculeCXCR4Weak signal
NCT01458288: Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg (1 week): TG-0054 (3.14 mg/kg) 7/7 | TG-0054 (3.14 mg/kg)+G-CSF 5/5
NCT01018979: Primary mobilization success: 2/4 patients in the TG-0054 2.24 mg/kg group (MM 1, NHL 1) vs 1/3 patients in the 3.14 mg/kg group (MM 1); no p-value or confidence interval reported.
CemsidomidePhase 2Small moleculeCereblon E3 ubiquitin-ligasenot yet gradedNo reviewed efficacy summary in this indication
Hrain Anti-BCMA CAR-TPhase 2Cell therapyBCMAWeak signalFeatured results are safety only in this race
HRC0202Phase 2Cell therapyBCMAWeak signalFeatured results are safety only in this race
Iopofosine I-131Phase 2Radiopharmaceuticalphospholipid ether (selective lipid raftWeak signal
NCT02278315: The phase 1 dose-escalation and safety study enrolled 31 patients with relapsed or refractory multiple myeloma who had received a median of four prior lines of therapy. It established 31.25 mCi/m2 as the maximum tolerated single dose and identified 20 mCi/m2 administered twice, one week apart, as the highest evaluated fractionated dose regimen.
LMY-920Phase 2Cell therapyBCMA / TACInot yet gradedNo reviewed efficacy summary in this indication
RAPA-201Phase 2Cell therapyRapamycin-resistant autologous T-cell therapyWeak signal
NCT04176380: Overall response rate: 9/14 patients (64%) achieved disease remission (IMWG criteria) - 8 partial responses, 1 stringent complete response.
YKST02Phase 2Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD4045Phase 1/2Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
BCMA CAR-NK (Shenzhen Pregene Biopharma)Phase 1/2Cell therapyBCMAWeak signalNo reviewed efficacy summary in this indication
BCMA-Targeted Prime CAR-T Cells (Chongqing Precision Biotech)Phase 1/2Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
BelantamabPhase 1/2Monoclonal antibodyBCMAnot yet gradedNo reviewed efficacy summary in this indication
CT071Phase 1/2Cell therapyGPRC5Dnot yet gradedNo reviewed efficacy summary in this indication
EltanexorPhase 1/2—XPO1 (exportin-1)Weak signalNo reviewed efficacy summary in this indication
EzobresibPhase 1/2Small moleculeBETnot yet gradedNo reviewed efficacy summary in this indication
Galinpepimut-SPhase 1/2VaccineWT1 (Wilms Tumor-1 protein)not yet gradedNo reviewed efficacy summary in this indication
GIC-102Phase 1/2Cell therapyAllogeneic natural killer (NK) cell therapy (non-CAR)Weak signalNo reviewed efficacy summary in this indication
HuL001Phase 1/2Monoclonal antibodyENO1 (alpha-enolase 1)not yet gradedNo reviewed efficacy summary in this indication
ICP-490Phase 1/2Small moleculeCereblon E3 ubiquitin-ligaseWeak signalNo reviewed efficacy summary in this indication
STI-6129Phase 1/2Antibody–drug conjugateCD38not yet gradedNo reviewed efficacy summary in this indication
CID-103Phase 1Monoclonal antibodyCD38Weak signalFeatured results are safety only in this race
SAR442085DiscontinuedBiologic (subtype unspecified)CD38Weak signalFeatured results are dose-finding only in this race

Large race: only the 73 furthest-along competitors are listed; 95 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Compare side by side

5 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

(47 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Isatuximab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
November 2026 (2)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2026-11 · NCT06517017 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaActive not recruiting
Est. primary completion 2026-11-30 · NCT03989414 · CT.gov ↗
What to watch
December 2026 (2)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2026-12-01 · NCT06832865 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2026-12-31 · NCT04883242 · CT.gov ↗
What to watch
2027 (17)
April 2027 (5)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT05558319 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-04-01 · NCT04835129 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-04-01 · NCT06356571 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-04-05 · NCT03319667 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-04-30 · NCT02960555 · CT.gov ↗
What to watch
May 2027 (1)
Phase 1AL AmyloidosisActive not recruiting
Est. primary completion 2027-05-06 · NCT04754945 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Blood Cancer, Refractory Immune CytopeniasActive not recruiting
Est. primary completion 2027-06-29 · NCT05873205 · CT.gov ↗
What to watch
July 2027 (2)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-07 · NCT07479979 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-07 · NCT05346809 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2/3Multiple MyelomaRecruiting
Est. primary completion 2027-08 · NCT05665140 · CT.gov ↗
What to watch
September 2027 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-09-13 · NCT04643002 · CT.gov ↗
What to watch
October 2027 (3)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2027-10-09 · NCT07789522 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2027-10-09 · NCT07828522 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-10-15 · NCT04850599 · CT.gov ↗
What to watch
December 2027 (3)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-12 · NCT04891809 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT04558931 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT05776979 · CT.gov ↗
What to watch
2028 (12)
March 2028 (3)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-03 · NCT05272826 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-03-25 · NCT05137054 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-03-31 · NCT07045909 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-05-01 · NCT07585760 · CT.gov ↗
What to watch
June 2028 (2)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2028-06 · NCT03617731 · CT.gov ↗
What to watch
Phase 1/2Aplastic AnemiaRecruiting
Est. primary completion 2028-06-30 · NCT07714512 · CT.gov ↗
What to watch
July 2028 (1)
Phase 4Multiple MyelomaNot yet recruiting
Est. primary completion 2028-07 · NCT07334535 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Multiple MyelomaEnrolling by invitation
Est. primary completion 2028-11-30 · NCT05669989 · CT.gov ↗
What to watch
December 2028 (4)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2028-12 · NCT04786028 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2028-12 · NCT06216158 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-12-31 · NCT05922501 · CT.gov ↗
What to watch
Phase 2/3Multiple MyelomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07732712 · CT.gov ↗
What to watch
2029 (6)
January 2029 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-01-11 · NCT07764978 · CT.gov ↗
What to watch
June 2029 (2)
Phase 2T-ALLRecruiting
Est. primary completion 2029-06 · NCT06648889 · CT.gov ↗
What to watch
Phase 2Plasma Cell Leukemia (PCL)Recruiting
Est. primary completion 2029-06-30 · NCT07652905 · CT.gov ↗
What to watch
July 2029 (1)
Phase 1/2Multiple MyelomaNot yet recruiting
Est. primary completion 2029-07-01 · NCT07601100 · CT.gov ↗
What to watch
December 2029 (2)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-12-01 · NCT04240054 · CT.gov ↗
What to watch
Phase 2Primary Plasma Cell LeukemiaRecruiting
Est. primary completion 2029-12-30 · NCT07903623 · CT.gov ↗
What to watch
2030 (2)
October 2030 (1)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2030-10-14 · NCT04270409 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2030-12 · NCT05344833 · CT.gov ↗
What to watch
2032 (1)
November 2032 (1)
Phase 2Smouldering MyelomaRecruiting
Est. primary completion 2032-11-01 · NCT06762769 · CT.gov ↗
What to watch
2033 (2)
May 2033 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2033-05-28 · NCT05145400 · CT.gov ↗
What to watch
October 2033 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2033-10-01 · NCT07624513 · CT.gov ↗
What to watch
2035 (1)
March 2035 (1)
Phase 2/3Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2035-03-15 · NCT06860269 · CT.gov ↗
What to watch
2036 (1)
September 2036 (1)
Phase 1/2Multiple MyelomaNot yet recruiting
Est. primary completion 2036-09-30 · NCT07600151 · CT.gov ↗
What to watch
2039 (1)
March 2039 (1)
Phase 3Multiple MyelomaNot yet recruiting
Est. primary completion 2039-03 · NCT07903506 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

10 July 2026ApprovalFDA approves subcutaneous Sarclisa Escena with on-body injector
US, FDA · Source ↗
19 June 2026ApprovalSarclisa SC approved in Japan for multiple myeloma
JP, MHLW · Source ↗
8 June 2026ApprovalEU approval of Sarclisa subcutaneous via on-body injector
EU, European Commission · Source ↗
25 July 2025ApprovalSarclisa approved in the EU for transplant-eligible newly diagnosed multiple myeloma
EU, EMA · Source ↗
9 January 2025Topline resultIRAKLIA phase 3 subcutaneous Sarclisa met co-primary endpoints